Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer

NCT00323869 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Bevacizumab
DRUG: Gemcitabine
DRUG: Carboplatin

Sponsor

Stanford University

Collaborators

[object Object]
[object Object]